On March 2022 the EU, South Africa, India and the U.S. reached a compromise on a waiver on IPR for coronavirus products (known as the TRIPS waiver). This webinar provides an overview of the challenges faced during the pandemic, and the impact of the TRIPS waiver to innovation, global public health, global collaboration, the patent system etc, as well as analyzes which are the right tools to prepare for the next pandemic.
Read paper from Paola Dabbicco, "IP Role in Covid Times: Compulsory Licensing, IP Waivers, and Other Initiatives", here.
